Skip to main content
Home
  • Cervical cancer
  • Vaginitis
  • STIs
  • Cervical cancer
    • Cervical Cancer Screening
      • What is HPV?
      • Different HPV genotypes
      • From HPV infection to cancer
      • Not all high-risk HPV genotypes are the same
      • The burden of cervical cancer
      • HPV vaccination has changed the landscape
      • Cervical cancer screening methods
      • Understanding HPV tests
      • Many HPV assays can hide the true risk
      • From HPV genotype to risk stratification and management
    • Patient Management
      • Offer your patients the personalized management they deserve
      • Why is HPV 31 important?
      • Meet Tianna, a 35-year-old who tested positive for HPV 31
      • Meet Grace, who has a persistent infection with the same HPV type
      • Meet Maya, who cleared one HPV type and then tested positive for another
    • Extended Genotyping
      • What does “extended genotyping” mean in the context of HPV testing?
      • FDA-approved HPV assays
      • HPV 31 identification
      • Genotype-specific HPV persistence
      • Enhance clinical management
    • BD Onclarity™ HPV Assay
      • The most comprehensive HPV test results you can get
      • What if identifying HPV 31 could make the difference?
      • HPV persistence tracking for the most high-risk genotypes
      • HPV test results that you can trust
      • Pap smear guidelines are changing, our HPV test can adapt
      • Compare FDA-approved HPV assays
      • BD Onclarity™ FDA trial
    Group of women stretching in a yoga room
    What is HPV?

    Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States (Genital HPV infection, CDC).

    Woman smiling in front of a colorful wall
    Different HPV genotypes

    There are more than 200 different types of HPV, around 40 types of HPV that affect the genital area, and 14 clinically relevant high-risk HPV genotypes. The different types of HPV are given numbers and known as HPV genotypes.

    Woman looking to the rain through a window
    From HPV infection to cancer

    Someone who develops an HPV infection can go years without having any symptoms. Most of the time HPV goes away on its own, other times it can cause genital warts, precancer or cancer.

    Group of people smiling
    Not all high-risk HPV genotypes are the same

    There are differences not only in the prevalence of the HPV genotypes, but also in the risk of those genotypes to cause cervical cancer.

    Woman and girl sitting behind a tablet
    The burden of cervical cancer

    Almost all cervical cancer can be prevented by HPV vaccination, but vaccination isn’t enough because the vaccine coverage is about half of the young population.

    Girl smiling on woman's back
    HPV vaccination has changed the landscape

    There are two different types of HPV vaccines in the US.

    Old and young ladies looking at a computer
    Cervical cancer screening methods

    There are three common cervical cancer screening paradigms in the US.

    Doctor talking with other woman
    Understanding HPV tests

    A variety of HPV tests can be used to detect HPV genotypes and determine a woman's risk of developing cervical precancer and cancer.

    Young lady painting in her living room
    Many HPV assays can hide the true risk

    Persistence of HPV, with one of the hr-HPV genotypes, is necessary for the development of cervical precancer and cancer.

    From HPV genotype to risk stratification & management
    From HPV genotype to risk stratification and management

    A positive HPV test requires further investigation, and the 2019 American Society for Colposcopy and Cervical Pathology (ASCCP) cervical cancer management guidelines recommend a personalized risk-based management.

    Offer your patients the personalized management they deserve
    Offer your patients the personalized management they deserve

    An HPV test that individually identifies more HPV types empowers you to make more informed decisions and better manage your patients.

    Woman kissing a boy on the nose
    Why is HPV 31 important?

    As the vaccinated population increases, HPV 16 and 18 are decreasing in prevalence, making it crucial to identify the other high-risk HPV genotypes.

    Meet Tianna, a 35-year-old who tested positive for HPV 31
    Meet Tianna, a 35-year-old who tested positive for HPV 31

    HPV 31 poses a higher risk of precancer as compared to HPV 18. Learn how individually identifying HPV 31 can benefit your patients like Tianna.

    Meet Grace, who has a persistent infection with the same HPV type
    Meet Grace, who has a persistent infection with the same HPV type

    Type-specific HPV persistence is the number one risk factor for cervical precancer and cancer. Learn how individually identifying more HPV types can help your patients like Grace.

    Maya
    Meet Maya, who cleared one HPV type and then tested positive for another

    HPV clearance with new HPV type detection lowers the risk for cervical cancer compared to having the same type. Learn how identifying more HPV types can change how you manage your patients like Maya.

    Smiling woman in a swimming pool
    What does “extended genotyping” mean in the context of HPV testing?

    Extended genotyping allows for a more precise way to measure your patient’s risk for developing cervical precancer and cancer vs. a pooled, high-risk assay.

    Five smiling women sitting around a party table
    FDA-approved HPV assays

    There are currently 5 FDA-approved HPV assays – each has a different number of results, based on the different hr-HPV genotypes detected and whether these genotypes are reported as a grouped result or as an individual result.

    Two doctors talking together in an hospital corridor
    HPV 31 identification

    Only an HPV assay with extended genotyping can individually identify hr-HPV genotypes beyond HPV 16 and 18, including HPV 31, which poses a similar risk for cervical precancer as compared to HPV 18 and should be managed similarly.

    Family smiling on a couch
    Genotype-specific HPV persistence

    Genotype-specific HPV persistence is the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotype.

    Little girl hugging and kissing a smiling lady
    Enhance clinical management

    Extended genotyping provides specific, actionable insights on an extended set of HPV genotypes.

    Two girls laying in a tent look at a tablet
    The most comprehensive HPV test results you can get

    Only the BD Onclarity™ HPV Assay provides you with the most comprehensive HPV test results available on the market today. Get the information you need to more precisely assess her risk of cervical cancer.

    Smiling woman painting a chair outside with yellow color
    What if identifying HPV 31 could make the difference?

    Not all HPV tests can identify HPV 31. The BD Onclarity™ HPV Assay is the only FDA-approved HPV test that provides an individual result for HPV 31.

    Daughter and mother doing yoga in a room
    HPV persistence tracking for the most high-risk genotypes

    Multiple studies conclude that genotype-specific high-risk HPV persistence is the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotype.

    Woman with two girls looking at a vegetable in a garden
    HPV test results that you can trust

    The unique design of the BD Onclarity™ HPV Assay gives you the detailed and accurate results that you need to enhance your patient's care experience.

    Standing woman looking at a tablet in a living room
    Pap smear guidelines are changing, our HPV test can adapt

    The BD Onclarity™ HPV Assay is FDA-approved for the three most common screening paradigms and for extended genotyping, offering the flexibility you need to adapt to changing screening guidelines.

    Smiling woman in a meeting room looking through the window
    Compare FDA-approved HPV assays

    An overview of FDA-approved HPV assays

    Doctor talking with nurses
    BD Onclarity™ FDA trial

    The BD Onclarity™ HPV Assay was extensively tested among women of different ages, ethnicities, and vaccination status in a prospective, multicenter clinical trial that enrolled more than 33,000 women.

  • Vaginitis
    • Vulvovaginitis
      • Vulvovaginitis: how it affects women and challenges the healthcare system
      • What is the cause of vulvovaginitis?
      • Bacterial vaginosis during pregnancy: potential complications
    • Diagnostic challenges
      • Vaginitis testing: from traditional culture to molecular
      • Recurring vaginal infections: help stop the cycle
      • Candida vulvovaginitis: the species matters
    • BD MAX™ Vaginal Panel
      • Vaginitis diagnosis made simple and clear
      • Compare FDA-cleared vaginitis tests
      • Identify vaginitis and STI co-infection from visit one
      • Flexible testing with various sample types
      • Coverage and reimbursement customer support
    Vulvovaginitis: how it affects women and challenges the healthcare system
    Vulvovaginitis: how it affects women and challenges the healthcare system

    Vulvovaginitis is the most common reason that women visit their primary care providers for a gynecologic-related issue in the US, resulting in 10 million office visits annually.

    What is the cause of vulvovaginitis?
    What is the cause of vulvovaginitis?

    Vulvovaginitis symptoms can have different causes that require a specific treatment, which makes proper diagnosis critical.

    Bacterial vaginosis during pregnancy: potential complications
    Bacterial vaginosis during pregnancy: potential complications

    Left untreated, women with vaginitis can develop severe complications such as pelvic inflammatory disease, fertility issues, and adverse pregnancy outcomes.

    Vaginitis testing: from traditional to molecular
    Vaginitis testing: from traditional culture to molecular

    The subjectivity and lack of sensitivity associated with traditional in-clinic testing leads to ~40% of women failing to receive a proper diagnosis after an initial primary care visit.

    Recurring vaginal infections: help stop the cycle
    Recurring vaginal infections: help stop the cycle

    Symptom overlap and co-infections may result in incorrect diagnosis and inadequate treatment, leading to recurrent and persistent infections.

    Candida vulvovaginitis: the species matters
    Candida vulvovaginitis: the species matters

    Traditional methods do not allow for the differentiation of Candida species. By identifying the species, you can determine the right approach – and avoid creating treatment resistance and recurring vaginitis.

    Vaginitis diagnosis made simple and clear
    Vaginitis diagnosis made simple and clear

    The BD Vaginal Panel is a comprehensive diagnostic test that directly detects the 3 most common infectious causes of vaginitis in one test, with one swab.

    Compare FDA-cleared vaginitis tests
    Compare FDA-cleared vaginitis tests

    There are currently 4 FDA-cleared molecular assays that use PCR amplification for the diagnosis of vaginitis and/or bacterial vaginosis.

    Identify vaginitis and STI co-infection from visit one
    Identify vaginitis and STI co-infection from visit one

    Vaginitis and STI co-infection is common: 25% of women with BV or VVC also had an STI. BD offers solutions that help provide a comprehensive diagnosis from the start.

    Flexible testing with various sample types
    Flexible testing with various sample types

    With a wide variety of compatible sample types, you have the flexibility to adapt to your patients needs.

    Coverage and reimbursement customer support
    Coverage and reimbursement customer support

    BD is committed to supporting physician offices, hospitals and laboratories that utilize the BD Vaginal Panel. That’s why we provide the following resources and services to help our customers navigate coverage and reimbursement challenges.

  • STIs
    • Sexually Transmitted Infections
      • CT, GC and TV infections
      • Chlamydia trachomatis (CT)
      • Neisseria gonorrhoeae (GC)
      • Trichomonas vaginalis (TV)
    • Diagnostic Challenges
      • Protect women from the consequences of infection
      • Follow STI Testing Guidelines
    • BD CTGCTV2 assay
      • Comprehensive STI testing with a single swab
      • A wide variety of samples to meet all patient needs
      • Don't miss co-infection with vaginitis
    Three women laughing with yoga mat in their hands
    CT, GC and TV infections

    Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) are the most prevalent non-viral causes of sexually transmitted infections and accounted for ~$1.1 billion in direct medical costs in 2018.

    Three smiling people making selfie picture
    Chlamydia trachomatis (CT)

    Chlamydia – caused by infection with Chlamydia trachomatis (CT) bacterium – is the most frequently reported bacterial sexually transmitted infection in the United States.

    Smiling couple sitting in a train and looking outside
    Neisseria gonorrhoeae (GC)

    Gonorrhea – caused by infection with Neisseria gonorrhoeae (GC) bacterium – is the second most commonly reported bacterial sexually transmitted infection in the United States.

    Smiling couple walking in the woods with backpacks
    Trichomonas vaginalis (TV)

    Trichomoniasis - caused by infection with the parasite Trichomonas vaginalis - is the most prevalent non-viral STI worldwide.

    Three women smiling together
    Protect women from the consequences of infection

    STIs are on the rise and remain a significant public health concern.

    Man carrying smiling woman on his back
    Follow STI Testing Guidelines

    Following STI testing guidelines may help identify asymptomatic cases of infection and protect them from the consequences of STIs.

    Smiling couple talking when walking in the streets at night
    Comprehensive STI testing with a single swab

    The BD CTGCTV2 assay is a 3-in-1 FDA-cleared test designed to detect the 3 most prevalent non-viral sexually transmitted infections simultaneously and separately.

    Four smiling women sitting at a table with dishes
    A wide variety of samples to meet all patient needs

    The BD CTGCTV2 assay can be run on patient- and clinician-collected vaginal swabs*, urine samples, endocervical swabs**, and on liquid-based cytology media (PreservCyt)**, with similar performance.

    Two young women laughing when sitting at a table
    Don't miss co-infection with vaginitis

    Vaginitis and STI co-infection is common. Identify it from visit 1, with one swab.

Home
  • Cervical cancer
    • Cervical Cancer Screening
      • What is HPV?
      • Different HPV genotypes
      • From HPV infection to cancer
      • Not all high-risk HPV genotypes are the same
      • The burden of cervical cancer
      • HPV vaccination has changed the landscape
      • Cervical cancer screening methods
      • Understanding HPV tests
      • Many HPV assays can hide the true risk
      • From HPV genotype to risk stratification and management
    • Patient Management
      • Offer your patients the personalized management they deserve
      • Why is HPV 31 important?
      • Meet Tianna, a 35-year-old who tested positive for HPV 31
      • Meet Grace, who has a persistent infection with the same HPV type
      • Meet Maya, who cleared one HPV type and then tested positive for another
    • Extended Genotyping
      • What does “extended genotyping” mean in the context of HPV testing?
      • FDA-approved HPV assays
      • HPV 31 identification
      • Genotype-specific HPV persistence
      • Enhance clinical management
    • BD Onclarity™ HPV Assay
      • The most comprehensive HPV test results you can get
      • What if identifying HPV 31 could make the difference?
      • HPV persistence tracking for the most high-risk genotypes
      • HPV test results that you can trust
      • Pap smear guidelines are changing, our HPV test can adapt
      • Compare FDA-approved HPV assays
      • BD Onclarity™ FDA trial
      The BD Onclarity™ HPV Assay is available out of BD SurePath™ and Hologic ThinPrep® Pap Test.
  • Vaginitis
    • Vulvovaginitis
      • Vulvovaginitis: how it affects women and challenges the healthcare system
      • What is the cause of vulvovaginitis?
      • Bacterial vaginosis during pregnancy: potential complications
    • Diagnostic challenges
      • Vaginitis testing: from traditional culture to molecular
      • Recurring vaginal infections: help stop the cycle
      • Candida vulvovaginitis: the species matters
    • BD MAX™ Vaginal Panel
      • Vaginitis diagnosis made simple and clear
      • Compare FDA-cleared vaginitis tests
      • Identify vaginitis and STI co-infection from visit one
      • Flexible testing with various sample types
      • Coverage and reimbursement customer support
  • STIs
    • Sexually Transmitted Infections
      • CT, GC and TV infections
      • Chlamydia trachomatis (CT)
      • Neisseria gonorrhoeae (GC)
      • Trichomonas vaginalis (TV)
    • Diagnostic Challenges
      • Protect women from the consequences of infection
      • Follow STI Testing Guidelines
    • BD CTGCTV2 assay
      • Comprehensive STI testing with a single swab
      • A wide variety of samples to meet all patient needs
      • Don't miss co-infection with vaginitis
Resources

Privacy | Terms of Use | Cookie Settings

Resources
Sound on Skip intro

Shaping the future of women's health

  • Cervical cancer
  • Vaginitis
  • STIs
10%
  1. Node
  • Cervical cancer
  • Vaginitis
  • STIs
  • Follow us
  • Cervical cancer
  • Vaginitis
  • STIs

BD, the BD logo, BD Onclarity, and BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners.
©2023 BD. All rights reserved.

Privacy | Terms of Use | Cookie Settings

Learn more about our BD Women’s Health solutions

This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.

Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.